HK1246183A1 - Hpv疫苗 - Google Patents

Hpv疫苗 Download PDF

Info

Publication number
HK1246183A1
HK1246183A1 HK18105733.1A HK18105733A HK1246183A1 HK 1246183 A1 HK1246183 A1 HK 1246183A1 HK 18105733 A HK18105733 A HK 18105733A HK 1246183 A1 HK1246183 A1 HK 1246183A1
Authority
HK
Hong Kong
Prior art keywords
cancer
infections
pharmaceutical compositions
treatment
methods
Prior art date
Application number
HK18105733.1A
Other languages
English (en)
Chinese (zh)
Inventor
奥尔林格 克劳斯
奧爾林格 克勞斯
莫纳思 汤玛斯
莉亚 安德斯
莫納思 湯瑪斯
施密特 莎拉
贝尔卡 耳舒拉
莉亞 安德斯
史温丁格 迈克尔
沃森 伊莉莎白
基埃弗曼 贝蒂娜
辛特拉姆斯科格勒 朱丽亚
貝爾卡 耳舒拉
富尔曼 格哈德
埃斯珀克 安德列亚斯
史溫丁格 邁克爾
科恩 凯萨琳
基埃弗曼 貝蒂娜
辛特拉姆斯科格勒 朱麗亞
富爾曼 格哈德
埃斯珀克 安德列亞斯
科恩 凱薩琳
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of HK1246183A1 publication Critical patent/HK1246183A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK18105733.1A 2015-06-10 2016-06-09 Hpv疫苗 HK1246183A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US62/173,805 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US62/254,410 2015-11-12
US201662331158P 2016-05-03 2016-05-03
US62/331,158 2016-05-03
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Publications (1)

Publication Number Publication Date
HK1246183A1 true HK1246183A1 (zh) 2018-09-07

Family

ID=56137292

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105733.1A HK1246183A1 (zh) 2015-06-10 2016-06-09 Hpv疫苗

Country Status (8)

Country Link
US (3) US10669315B2 (cg-RX-API-DMAC7.html)
EP (1) EP3307308A2 (cg-RX-API-DMAC7.html)
JP (2) JP7098330B2 (cg-RX-API-DMAC7.html)
CN (2) CN115197965A (cg-RX-API-DMAC7.html)
AU (2) AU2016274655B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987155A1 (cg-RX-API-DMAC7.html)
HK (1) HK1246183A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016198531A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
SG11201803474UA (en) 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
CA3039356A1 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) * 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
CA3069821A1 (en) * 2017-07-14 2019-01-17 Oncorus, Inc. Encapsulated polynucleotides and methods of use
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN108424925A (zh) * 2018-03-07 2018-08-21 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
KR20210093285A (ko) * 2018-11-13 2021-07-27 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
US20220001004A1 (en) * 2018-11-28 2022-01-06 The General Hospital Corporation T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
EP3986455A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
AU2020377504A1 (en) * 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
CA3160839A1 (en) * 2019-11-15 2022-05-09 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating hpv mrna
US11744885B2 (en) 2020-05-14 2023-09-05 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
JP2023527083A (ja) 2020-05-29 2023-06-26 ホオキパ バイオテック ジーエムビーエイチ アレナウイルスベクターを使用するがんの治療方法
AU2022244100A1 (en) 2021-03-23 2023-10-19 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025155938A1 (en) * 2024-01-18 2025-07-24 Aov Biopharma, Inc. Vaccine for prevention and treatment of human papilloma virus related cancer
WO2025191169A1 (en) * 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6869779B1 (en) * 1998-08-27 2005-03-22 Fuso Pharmaceutical Industries, Ltd. Nucleic acid sequence for potentiating the expression of useful gene and method therefor
IL145702A0 (en) * 1999-04-06 2002-07-25 Wisconsin Alumni Res Found Recombination influenza viruses for vaccines and gene theraphy
WO2004030636A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
CA2587493A1 (en) * 2004-11-30 2006-06-08 Aeras Global Tb Vaccine Foundation Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
ES2746150T3 (es) 2014-09-22 2020-03-04 Univ Minnesota Sistema de genética inversa para el virus Pichindé y métodos de uso
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
CA2967720C (en) * 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
ES3021881T3 (en) 2015-10-23 2025-05-27 Pasteur Institut Recombinant mopeia virus and vaccine platform
SG11201803474UA (en) 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
CA3023599A1 (en) 2016-05-18 2017-11-23 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
EP3986455A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
AU2020377504A1 (en) 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
JP2023527083A (ja) 2020-05-29 2023-06-26 ホオキパ バイオテック ジーエムビーエイチ アレナウイルスベクターを使用するがんの治療方法

Also Published As

Publication number Publication date
CA2987155A1 (en) 2016-12-15
CN107921117A (zh) 2018-04-17
JP2018518172A (ja) 2018-07-12
JP7098330B2 (ja) 2022-07-11
AU2021232660B2 (en) 2025-02-27
US20180179257A1 (en) 2018-06-28
WO2016198531A3 (en) 2017-01-19
US11407790B2 (en) 2022-08-09
US20210024584A1 (en) 2021-01-28
AU2016274655A1 (en) 2017-12-21
US20230086859A1 (en) 2023-03-23
US10669315B2 (en) 2020-06-02
AU2016274655B2 (en) 2021-06-17
EP3307308A2 (en) 2018-04-18
CN115197965A (zh) 2022-10-18
CN107921117B (zh) 2022-06-07
AU2021232660A1 (en) 2021-10-07
JP2022160401A (ja) 2022-10-19
WO2016198531A2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
HK1246183A1 (zh) Hpv疫苗
ZA201707524B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
WO2017030823A3 (en) Anti-tigit antibodies
MY197866A (en) Anti-cd27 antibodies
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
PH12018500569B1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
IN2014DN03054A (cg-RX-API-DMAC7.html)
MY187068A (en) Indole derivatives as dengue viral replication inhibitors
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EP3254693A4 (en) Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
LV15072A (lv) Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai